ERBB2 and breast cancer: Interestingly, Pten loss enhances MAPK activation and MEK inhibitor sensitivity in a mouse model of Her2/neu-driven breast cancer.(45) These findings indicate that persistent activation of MAPK is a dominant mechanism of resistance to FTIs even in the presence of PI3K pathway activation.